Cascade-Deaminase Complex for Base Editing Without DNA Cleavage

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional genome editing techniques require double-stranded DNA breaks, leading to cytotoxicity, chromosomal rearrangements, and low mutation efficiency, particularly in primate ova and unicellular microorganisms, and lack effectiveness in gene therapy and molecular breeding due to reliance on cleavage-based methods.

Innovation Solution

A method utilizing a Type I CRISPR-Cas system, specifically the Cascade complex from Escherichia coli, combined with a deaminase to convert nucleotides without cleaving DNA, allowing for targeted nucleotide modifications by recognizing specific PAM sequences, thereby expanding mutation introduction sites beyond the limitations of Type II CRISPR-Cas9.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional genome editing techniques using artificial nucleases are used, then sequence-specific DNA cleavage is achieved, but double-stranded DNA breaks cause cytotoxicity, chromosomal rearrangement, and reduced reliability

Engineering Contradiction:
Improvesequence-specific DNA cleavageVSAvoidcytotoxicity and chromosomal rearrangement
Core Design Contradiction:
Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and removes the harmful nuclease domain from the CRISPR-Cas9 system, retaining only the sequence-specific recognition capability through guide RNA and Cas protein binding, while eliminating the DNA cleavage function that causes cytotoxicity and chromosomal rearrangement

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention introduces a deaminase enzyme as an intermediary that performs base conversion instead of direct DNA cleavage. The deaminase acts as a mediator between the sequence-specific recognition complex and the DNA, enabling precise nucleotide modification without causing double-stranded breaks

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If Type II CRISPR-Cas9 system is used, then DNA cleavage capability is achieved, but mutation introduction sites are limited by PAM sequence requirements

Engineering Contradiction:
ImproveDNA cleavage capabilityVSAvoidmutation introduction site flexibility
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention removes the nuclease activity requirement from the system, allowing the CRISPR-Cas complex to function solely for sequence recognition and guiding deaminase to target sites without being constrained by PAM sequence requirements for cleavage

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the fundamental parameter of the editing mechanism from cleavage-based to base conversion-based, which alters the targeting constraints and enables mutation introduction at sites that would not be accessible to traditional Cas9 nucleases

Inventive Principle:
Principle #35Parameter changes

3Reliability

If deaminase alone is used without CRISPR system, then base conversion capability is achieved, but sequence-specific targeting is lost

Engineering Contradiction:
Improvebase conversion capabilityVSAvoidsequence-specific targeting
Core Design Contradiction:
ReliabilityVSMeasurement precision

Solution Approach 1:

The invention merges the sequence-specific recognition capability of the CRISPR-Cas complex with the base conversion capability of deaminase, creating a unified system that combines targeting precision with editing functionality without requiring DNA cleavage

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances safety by avoiding foreign DNA insertion and DNA breaks, increasing mutation efficiency and site flexibility, making it suitable for a wide range of biological materials and reducing toxicity, thus addressing the limitations of existing genome editing methods.

Implementation Method 1

deaminase that converts an amino group of a nucleic acid base to a carbonyl group

Methodology Applied
Scientific EffectDeamination reaction:

Data Source

PatentEP3348636B1Method for modifying genome sequence that specifically converts nucleobase of targeted DNA sequence, and molecular complex used in said method
Publication Date: 2021.12.01 KOBE UNIV
  • EP3348636B1 patent drawingFigure 1A~1E
  • EP3348636B1 patent drawingFigure 2
  • EP3348636B1 patent drawingFigure 3

AI summary

The present invention provides a method of modifying a targeted site of a double stranded DNA in a host cell, the method including introducing (a) a DNA encoding a crRNA containing a sequence complementary to a target strand of a target nucleotide sequence in the given double stranded DNA, and (b) a DNA encoding a protein group constituting Cascade and a nucleic acid base converting enzyme, in which the nucleic acid base converting enzyme is constituted in a form capable of forming a complex with any protein in the protein group, into the host cell to convert one or more nucleotides in the targeted site to other one or more nucleotides, or delete one or more nucleotides, or insert one or more nucleotides into said targeted site, without cleaving the double stranded DNA in the targeted site.